Previous 10 | Next 10 |
Biogen is beginning to have a trend change. Biogen is at the bottom of a trading range that goes back 10 years. Now may be a good time to initiate a position with earnings coming soon. As I look at price charts at the end of the week for potential buys or shorts I notice...
Gainers: Direxion Daily S&P Biotech Bull 3x Shares ETF ( LABU ) +45% . Axs 2X Innovation ETF ( TARK ) +35% . Direxion Daily Homebuilders & Supplies Bull 3x Shares ETF ( NAIL ) +27% . Direxion Daily Dow Jones Internet Bull 3X Shares ( W...
DexCom has a leading position in a huge and growing market of continuous glucose monitoring. Medical technology is a growing space, with powerful demographic forces leading to outsized long-term growth. The stock has pulled back to an entry point that has it a strong buy for a 5+ ...
Ublituximab used to be TGTX's second asset and a very large potential icing on the cake for the company. After umbralisib went down, ubli has become its lifeline. While data is consistently good, one wonders what the FDA asked for with the new data that led to a delay. F...
Starting with September 2021, LABU had a record sequence of nine consecutive months with negative returns. During the biotech downtrend from September 2021 to April 2022, LABD has returned 207%. During the biotech uptrend from April 2020 to January 2021, in only ten months, LABU h...
Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as e...
Microsatellite stable colorectal cancer patients who had a molecular response who took GRANITE combination exceeded mOS of 18 months and mOS has not yet been reached. The global market opportunity for colorectal cancer is expected to reach $18.5 billion by 2023. Results from the p...
Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the United Kingdom. PDUFA date for potential FDA approval of Yselty for...
The reasons of leveraged ETFs non-linear behavior. Drift dashboard of 22 leveraged ETFs. Lessons of SPXS history. The Direxion Daily S&P 500 Bear 3X Shares ETF ( SPXS ) is one of the most popular instruments to short the broad market for trading or hedging purpos...
BCYC was founded by a Nobel Prize winner. Hopefully, that will not be its only claim to fame. However, convincing proof of concept is another year away. Bicycle Therapeutics plc ( BCYC ) is co-founded by Nobel Prize winning molecular biologist Dr. Greg Winter, who is...
News, Short Squeeze, Breakout and More Instantly...
Direxion Daily S&P Biotech Bear 3X Shares Company Name:
LABD Stock Symbol:
NYSE Market:
2024-06-01 07:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-22 08:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-12 22:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...